The collaboration with Clínica Universidad de Navarra's CIMA Lab Diagnostics adds a single cell genomic layer to standard hematology workups, with initial availability limited to the EU and no disclosed financial terms.
For years, hematologists at Clínica Universidad de Navarra's CIMA Lab Diagnostics could count the abnormal cells in a patient's blood with flow cytometry, but the technique left a layer of information unread: the genomic architecture of the rare tumor clones driving the disease. A new commercial partnership with Predicta Biosciences is designed to fill that gap, attaching the company's GenoPredicta single-cell assay to CIMA's existing flow cytometry workflow for differential diagnosis, prognostic classification, and minimal residual disease monitoring across multiple blood cancers.
The collaboration, announced June 10 in a Predicta Biosciences press release covered by FierceBiotech, combines GenoPredicta's single-cell genomic readout with CIMA's flow cytometry capacity, a pairing the partners describe as filling a "missing element" in CIMA's hematology pipeline. Financial terms of the deal were not disclosed, and the initial footprint is limited to Spain and other EU countries.
GenoPredicta is the load-bearing piece. Predicta bills it as a precision-oncology tool that reads the genomic profile of individual tumor cells, including the rare clones that often escape detection in bulk sequencing or standard immunophenotyping. Flow cytometry excels at quantifying cell populations and sorting them by surface markers, but it does not see the DNA-level changes that increasingly drive classification and treatment selection in hematologic malignancies. The two modalities are complementary: flow cytometry identifies and counts the cells of interest, while GenoPredicta characterizes them at single-cell resolution.
The partners are targeting three concrete clinical tasks. Differential diagnosis, distinguishing between morphologically similar blood cancers that require different treatment paths. Prognostic classification, sorting patients into risk groups based on the genomic features of their disease. And minimal residual disease monitoring, the post-treatment tracking of trace tumor populations that often predicts relapse before conventional tools catch it. None of those uses constitutes regulatory approval of GenoPredicta as a standalone diagnostic, and the partnership announcement does not claim peer-reviewed validation of the assay's analytical performance.
Dr. Bruno Paiva, head of CIMA Lab Diagnostics, is the named partner-side executive quoted in the release. He frames the combination as addressing a workflow gap rather than introducing a new standard. The release also flags an upcoming presentation by Paiva at the European Hematology Association meeting in Stockholm, a forward-looking data presentation rather than peer-reviewed validation of the assay. Readers weighing the clinical significance should treat that EHA talk as a signal of forthcoming evidence, not a substitute for it.
Two structural limits shape how much weight the announcement can carry. First, "precision oncology specialist" is Predicta's own positioning language; the company has not, in the available material, published independent head-to-head data showing GenoPredicta outperforms existing single-cell or bulk genomic approaches in routine hematology practice. Second, the EU-only launch and undisclosed financial terms mean the partnership is best read as a commercial distribution and assay-pairing arrangement, not a market-shifting commercial event. Independent context on EU regulatory and reimbursement pathways for molecular hematology diagnostics is not part of the announcement, and any claim about near-term patient access beyond the announced footprint would outrun the source.
What to watch next: the EHA presentation in Stockholm for any disclosed performance data on GenoPredicta in the three named use cases; any subsequent filings or peer-reviewed publications from CIMA or Predicta; and whether the partnership extends beyond the EU, or attracts a second academic or commercial flow cytometry partner. For now, the deal is a precise operational pairing with a defined clinical scope, not a validation of the underlying assay.